Perrigo Feels Chill From Q3 Results Due To ‘Unfulfilled’ Demand On Supply Chain Disruptions
Executive Summary
“Unfulfilled orders' from retailers and other product distributors due to supply chain disruptions slowed revenues, net income and earnings per share during the quarter and prompted lower full-year guidance while also leaving analysts with doubts.
You may also be interested in...
US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.
Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19
Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.
If Successful, HRA Pharma Acquisition Will Complete Perrigo’s Pivot Towards Self-Care
If its acquisition of France's HRA Pharma completes, Perrigo will have “enough growth in our back pocket for the next three to five years without making any further acquisitions,” says the firm’s UK & Ireland chief, Neil Lister, in an exclusive interview with HBW Insight.